Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Distribution, selling, general and administrative expenses

Restructuring and employee severance

Amortization and other acquisition-related costs

Impairments and (gain)/loss on disposal of assets, net

Litigation (recoveries)/charges, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Cardinal Health

Cordis develops and manufactures medical devices for diagnostics and interventional procedures to treat patients suffering from coronary and peripheral vascular diseases.On October 4, 2015, Cardinal Health announced that it has completed the acquisition of Johnson & Johnson's Cordis business for $1.944 billion.

Cordis

Cardinal Health, Inc. is a healthcare services and products company, which engages in the provision of customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, and physician offices. It also provides medical products and pharmaceuticals and cost-effective solutions that enhance supply chain efficiency. The firm operates through the Pharmaceutical and Medical segments. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products. The Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical, and laboratory products. The company was founded by Robert D. Walter in 1979 and is headquartered in Dublin, OH.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Cardinal Health reports strong Q3 results, focuses on Pharma growth

Cardinal Health's Q3 results demonstrated strong performance in the Pharma segment, while the Medical segment faced challenges. The company raised its guidance for the year and emphasized the importance of Red Oak Sourcing in maintaining market dynamics. Looking ahead, the company is focused on executing its medical improvement plan and maximizing shareholder value.

Cardinal Health reports stable Q2 growth, eyes Pharma segment

Cardinal Health's Q2 2023 performance showcased stability and growth in the Pharma segment, with a return to profitability in the Medical segment.
The company's strategic focus on executing key priorities and driving shareholder value creation is evident in its financial results.
Challenges such as international freight costs and supply chain headwinds are being addressed, while opportunities in COVID therapies, pricing strategy, and growth investments are being pursued.
Overall, Cardinal Health's revised outlook and strong performance in key segments position it for continued growth and financial success.

Cardinal Health reports robust Q3 earnings, eyes biosimilars for growth

Cardinal Health delivered strong financial performance in Q3 2023, driven by robust growth in the Pharma segment.
While facing challenges in the Medical segment, the company remains focused on mitigating inflation and maximizing shareholder value.
With a positive outlook on future growth opportunities, Cardinal Health aims to address cost pressures and drive profitability.

Cardinal Health achieves record results, raises guidance for fiscal '24

Cardinal Health's strong performance in Q4 and fiscal year 2023, coupled with strategic initiatives and guidance raise, position the company for continued growth and success.
Challenges such as inflation mitigation and cost pressures are being addressed, while opportunities in organic growth and strategic investments pave the way for future profitability.
The company's focus on advancing Pharma, executing the Medical Improvement Plan, and maximizing shareholder value creation underscores its commitment to sustained growth and value creation.

Cardinal Health reports strong Q1 earnings, raises guidance for FY24

Cardinal Health's Q1 2024 earnings call showcased robust performance, with profit growth in both Pharma and Medical segments. The company raised EPS guidance, demonstrated strong cash flow generation, and emphasized customer service and shareholder value creation. Challenges include managing margins, nonoperating items, and commodity price impacts, while opportunities lie in healthcare sector growth, innovation, and market dynamics.

Cardinal Health reports robust Q2 earnings, raises EPS guidance

Cardinal Health's Q2 performance reflects strong revenue growth, improved cash flow, and raised EPS guidance, supported by strategic acquisitions and growth initiatives.
While facing challenges from nonrecurring adjustments and SG&A growth, the company remains focused on core businesses and driving future growth opportunities.
With a positive outlook on market-driven growth, cost management, and strategic priorities, Cardinal Health aims to sustain its momentum and deliver value to shareholders.

Cardinal Health reports robust Q3 earnings, eyes growth opportunities ahead

Cardinal Health's Q3 performance reflects strong financial results and strategic progress across key segments, with raised guidance for fiscal '24 and '25.
The company faces challenges such as managing customer transitions and inflationary impacts but is well-positioned to capitalize on growth opportunities.
By focusing on cost optimization, strategic partnerships, and customer-centric solutions, Cardinal Health aims to drive sustained growth and profitability.
Investments in technology, brand growth, and operational efficiency underscore Cardinal Health's commitment to delivering value to shareholders and customers.

Cardinal Health excels in fiscal '24, raises guidance for '25

Cardinal Health's strong performance in fiscal year '24, highlighted by record financial results and strategic progress, positions the company for continued success.
Despite challenges such as market dynamics and customer transitions, the company's raised guidance for fiscal year '25 underscores confidence in future growth.
By capitalizing on strengths like revenue growth in key segments and making strategic investments, Cardinal Health is poised to navigate challenges and seize opportunities for sustained growth.

Cardinal Health reports strong Q1 performance and raises fiscal guidance

Cardinal Health's Q1 performance showed strength in Pharma and Specialty Solutions despite revenue decrease.
Challenges in GMPD segment and nuclear supply disruptions are being addressed for minimal impact.
Opportunities lie in continued cost reductions, growth normalization, and operational improvements.
Overall, Cardinal Health is well-positioned to navigate challenges and capitalize on growth opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

McKesson

United Therapeutics

Virtusa

A lower PEG ratio, preferably less than 1, indicates both undervaluation and solid future growth potential of a stock.

4 Finest Value Stocks Based on Discounted PEG

Abercrombie & Fitch

Anixter

Brookdale Senior Living

Fluor

One of the well-accepted investment policies is to maintain a diversified portfolio for reaping handsome returns, irrespective of the market volatility.

5 Broker-Friendly Stocks to Ride Out the Coronavirus Scare

Cardinal Health (CAH) seems to be a good value pick, as it has decent revenue metrics to back up its earnings, and is seeing solid earnings estimate revisions as well.

Looking for Value? Why It Might Be Time to Try Cardinal Health (CAH)

American Equity Investment Life

Blackrock Inc

Top Ranked Momentum Stocks to Buy for February 20th

AmerisourceBergen

Leading drug distributor stocks remain sensitive to ongoing opioid settlement negotiations. Here are crucial technical levels to watch.

Drug Distributor Stocks in Focus on Opioid Settlement News

Cardinal Health (CAH) is gaining from diversified product portfolio and robust pharmaceutical segment.

Here's Why You Should Invest in Cardinal Health Stock Now

The three big drug distributors have been in talks for months in the hopes of finding a global settlement.

21 States Reject $18 Billion Bid to Settle Opioid Litigation

Johnson & Johnson

Shares of drug wholesalers, who have held talks to settle opioid litigation, sank in morning trading Friday, after The Wall Street Journal reported that 21 states had rejected an $18 billion settlement offer. Shares of AmerisourceBergen Corp.

Drug wholesaler stocks falls after WSJ report that states rejected opioid settlement offer

DaVita

Legg Mason

PG&E

PEG-based investing can be more rewarding with the addition of a few other relevant parameters.

5 Great GARP Stocks Based on Discounted PEG

Like the majority of investors, you're most likely working on a retirement portfolio that will provide a large enough nest egg to give you a comfortable retirement. Make sure you know all about what financial planners call the accumulation and distribution phases of retirement planning.

Retirees Should Know These 3 Facts About Required Minimum Distributions - February 13, 2020

Honeywell

Premier

Coronavirus is ravaging China and several other countries. With no cure yet, health officials are struggling to stop its spread.

5 Stocks to Watch as Fatalities Due to Coronavirus Rise

Cardinal Health (CAH) saw a big move last session, as its shares jumped nearly 11% on the day, amid huge volumes.

Cardinal Health (CAH) in Focus: Stock Moves 10.6% Higher

Cardinal (CAH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Cardinal (CAH) Hits 52-Week High, Can the Run Continue?

The healthcare company reported solid quarterly earnings and raised its fiscal full-year 2020 guidance.

Here's Why Cardinal Health Rose as Much as 13.7% Today

Cardinal Health's (CAH) CEO Mike Kaufmann on Q2 2020 Results - Earnings Call Transcript

Cardinal (CAH) delivered earnings and revenue surprises of 25.62% and 0.64%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Cardinal Health (CAH) Q2 Earnings and Revenues Surpass Estimates

ABIOMED

Becton, Dickinson and Co.

10X Genomics

Despite the ongoing US-China trade war, increased focus on innovation is likely to have driven performance of medical products players' quarterly performance.

Medical Products Stock Feb 6 Earnings Roster: BDX, CAH & More

Boston Scientific

CVS Health

The markets may be taking a dip, but these three healthcare stocks could be your portfolio's prescription as earnings season is in full swing.

3 Healthcare Stocks to Buy This Week Ahead of Earnings

Cardinal Health (CAH) fiscal second-quarter earnings are likely to reflect better-than-expected performance at Pharmaceutical and Medical segments.

What's in Store for Cardinal Health's (CAH) Q2 Earnings?

Cardinal (CAH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Cardinal Health (CAH) Q2 Earnings Expected to Decline

Colgate-Palmolive

McDonald's

These are some of the safest dividend stocks you can hold.

3 Dividend Aristocrats to Build Your Portfolio Around

Let's see if Cardinal Health (CAH) stock is a good choice for value-oriented investors right now from multiple angles.

Is Cardinal Health (CAH) a Solid Pick for Value Investors?

Caterpillar

Chubb

Lowe's

Nucor

Sherwin-Williams

Target

T. Rowe Price Group

Exxon Mobil

9 Dividend Blue Chips That Can Make You Rich

Cardinal Health (CAH) is gaining from diversified product portfolio and robust pharmaceutical segment. However, integration risks remain a concern.

Here's Why You Should Hold on to Cardinal Health Stock Now

AbbVie

Amarin Corporation Plc

Gilead Sciences

Novo Nordisk

Thermo Fisher Scientific

Politicians have investors in healthcare stocks nervous as the 2020 election nears. Here's a guide to which firms are good choices and which you should avoid.

News for Cardinal Health Stock (CAH)